Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EYPT
STRONG SELLEyePoint, Inc. · Healthcare · United States · $1.0B · Avg Vol: $18M/d
COMPANY DESCRIPTION
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing and commercializing innovative therapeutics for serious eye diseases. The company's proprietary Durasert technology provides sustained-release drug delivery, establishing a strong competitive moat in the ocular therapeutics market. It operates as a niche leader in long-acting treatments for retinal diseases like wet age-related macular degeneration.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.4M | 46.0M | 43.3M | 31.4M | -8.8% | 7.6M | 1.8M | 32.8M | 2.2% |
| EPS | -1.11 | -1.82 | -2.32 | -3.17 | — | -3.34 | -3.55 | -3.04 | — |
| Shares | 83.8M | 49.0M | 68.3M | 82.8M | -1.2% | 83.8M | — | — | — |
| Debt | 45.8M | 4.9M | 21.9M | 20.8M | -23.2% | 17.6M | — | — | — |
| Equity | 96.4M | 266.3M | 336.5M | 306.1M | 47.0% | — | — | — | — |
| Op CF | -65.0M | 1.9M | -126.2M | -240.1M | — | -267.5M | — | — | — |
| Inv CF | -17.3M | -3.3M | -219.4M | 68.6M | — | — | — | — | — |
| Fin CF | -0.7M | 187.1M | 164.0M | 173.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EYPT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EYPT | EyePoint, Inc.(you) | $1.0B | 2 | STRONG SELL |
| ODTX | Odyssey Therapeutics, Inc. | $896M | 3 | STRONG SELL |
| OLMA | Olema Pharmaceuticals, Inc. | $1.0B | 10 | STRONG SELL |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 8 | STRONG SELL |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.2B | 7 | STRONG SELL |
| SANA | Sana Biotechnology, Inc. | $885M | 9 | STRONG SELL |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.1B | 11 | STRONG SELL |
| AVLN | Avalyn Pharma Inc. | $1.2B | 9 | STRONG SELL |
| INBX | Inhibrx Biosciences, Inc. | $1.2B | 10 | STRONG SELL |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.6B | 5 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%